Review
Immunology
Hao Hu, Zhi-Yong Xu, Qian Zhu, Xi Liu, Si-Cong Jiang, Ji-Hua Zheng
Summary: A meta-analysis was conducted to assess the influence of brain metastases (BM) status on immunotherapy efficacy in advanced lung cancer. The results indicated that both BM and non-BM patients could obtain comparable survival benefits from immunotherapy, with no statistically significant difference between them.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Yanning Wang, Qianning Zhang, Chuansheng Chen, Yuxuan Hu, Liyun Miao, Yujie Zhou
Summary: This study evaluated the relative efficacy of immunotherapy compared to standard systemic therapy in advanced lung cancer patients with and without brain metastases. Results showed a survival benefit of immunotherapy for both patients with and without brain metastases, but patients without brain metastases benefited more. Subgroup analyses also indicated that tumor type may affect the efficacy of immunotherapy in patients with brain metastases.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Handai Xia, Wengang Zhang, Yuqing Zhang, Xiaoling Shang, Yanguo Liu, Xiuwen Wang
Summary: The effect of liver metastases on the efficacy of immune checkpoint inhibitors (ICIs) in lung cancer patients remains inconsistent and controversial. This study analyzed data from randomized controlled trials and observational studies and found that liver metastases do not significantly influence the overall survival benefit of ICIs in non-small cell lung cancer (NSCLC) patients. However, liver metastases may limit the overall survival benefit in small cell lung cancer (SCLC) patients. Liver metastasis has the potential to be an independent prognostic risk factor for lung cancer patients receiving ICI treatment in clinical practice.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Fernanda O. Novais, Camila Farias Amorim, Phillip Scott
Summary: Cutaneous leishmaniasis presents a wide spectrum of clinical manifestations, with severe cases often not responding to anti-parasitic drugs. Host-directed therapies offer a novel approach to improve clinical outcomes and could be a valuable tool in modulating disease severity. It is important to tailor these therapies for specific types of leishmaniasis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Anne Petzold, Theresa Steeb, Anja Wessely, Tobias Schatton, Carola Berking, Markus Heppt
Summary: This study compared different treatments for advanced cutaneous squamous cell carcinoma and found that immune checkpoint blockade (ICB) showed superior efficacy in terms of overall survival and progression-free survival compared to other treatment options.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Emily L. Clarke, Ryckie G. Wade, Derek Magee, Julia Newton-Bishop, Darren Treanor
Summary: The current subjective histopathological assessment of cutaneous melanoma is challenging, and the application of image analysis algorithms to histological images may improve workflow and prognostication. This review aimed to evaluate the accuracy of existing image analysis algorithms applied to digital histological images of cutaneous melanoma.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Neil K. Mehta, Andraia R. Li, Shaun A. Nguyen, John M. Kaczmar, David M. Neskey, Terry A. Day
Summary: This study evaluated the efficacy of ICIs in advanced CSCC, showing promising results with high objective response rates and disease control rates. The tolerability of ICIs was good, warranting further trials and research.
Article
Oncology
Ramon Yarza, Mateo Bover, Mercedes Herrera-Juarez, Macarena Rey-Cardenas, Luis Paz-Ares, Jose A. Lopez-Martin, John Haanen
Summary: This study conducted a systematic review and meta-analysis to assess the primary efficacy of TCR-based adoptive cell therapy in cutaneous melanoma. The results showed promising antitumor activity and survival for TCR-T therapy, with a significantly higher benefit for cancer/testis antigen targeting cells.
Article
Oncology
Ramon Yarza, Mateo Bover, Mercedes Herrera-Juarez, Macarena Rey-Cardenas, Luis Paz-Ares, Jose A. Lopez-Martin, John Haanen
Summary: TCR-based ACT has shown promising results in treating metastatic cutaneous melanoma, with a notable antitumor activity and survival benefit.
Review
Gastroenterology & Hepatology
Kai Xiong, Tiantian Bao, Yibo Cao, Wenting Hu, Jia Deng, Jiang Chen, Tianbao Xiao
Summary: The standard of care for locally advanced rectal cancer has shifted from radical surgery to multimodality treatment. A meta-analysis compared the efficacy and safety of total neoadjuvant therapy (TNT) and standard chemoradiotherapy (CRT) in randomized controlled trials. The results showed that TNT improved pathological complete response and survival outcomes, and reduced the risk of distant metastasis compared with standard CRT.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2023)
Review
Oncology
William C. Chen, Ulysis H. Baal, Joe D. Baal, Jon S. Pai, Lauren Boreta, Steve E. Braunstein, David R. Raleigh
Summary: This systematic review and meta-analysis found that stereotactic radiosurgery for brainstem metastases is effective and safe, and comparable to SRS for nonbrainstem brain metastases, indicating that patients with BSM should be considered for clinical trials of SRS.
Review
Biochemistry & Molecular Biology
Cosimo Di Raimondo, Flavia Lozzi, Pier Paolo Di Domenico, Elena Campione, Luca Bianchi
Summary: Melanoma, the deadliest form of skin cancer, accounts for almost 90% of skin cancer mortality. Despite advances in immune and targeted therapies, many patients still experience disease progression. Skin metastases, a common occurrence in melanoma, can be treated through various methods including surgery, injections, and systemic therapies. Further research is needed to understand the underlying mechanisms and differences in behavior and prognosis among melanoma patients with skin metastases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Iqra Ijaz, Muhammad Naveed Shahzad, Hossein Hosseinifard, Shuya Liu, Masoud Ostadi Sefidan, Lubna Ejaz Kahloon, Saber Imani, Zhong Hua, Yu Qin Zhang
Summary: Uterine leiomyosarcoma (uLMS) is a aggressive mesenchymal neoplasm with a poor prognosis. The most effective treatment regimen for uLMS patients is still uncertain. Through a meta-analysis and meta-regression analysis, we evaluated different treatments and their outcomes for advanced, metastatic, and relapsing uLMS patients. The results showed that monotherapy with alkylating agents and protein kinase inhibitors had favorable prognoses. Combination therapies of anthracycline plus alkylating therapy and gemcitabine plus docetaxel were the most beneficial as first-line and second-line chemotherapies, respectively. Subgroup analysis revealed that dual-regimen therapies were practical choices for stages III-IVb uLMS patients with distant metastases. Neoadjuvant chemotherapy and local radiotherapy showed favorable outcomes for patients with earlier stages of distant relapsed uLMS. These findings can guide clinical practice and lead to better prognoses for uLMS patients.
Article
Dermatology
Dong Min Shin, Yeon Joo Jung, Heeyeon Kim, Se Jin Oh, Joonho Shim, Jong Hee Lee, Dong-Youn Lee, Jihye Park
Summary: This study aimed to identify primary cancers associated with cutaneous metastasis and analyze survival rates at an advanced stage of metastasis in a tertiary center in Korea. The results showed that breast cancer was the most common primary cancer leading to cutaneous metastasis, followed by lung cancer, stomach cancer, colorectal cancer, among others. The overall median survival period for cutaneous metastasis patients was 22 months.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Oncology
Salvatore Crisafulli, Lucrezia Bertino, Andrea Fontana, Fabrizio Calapai, Ylenia Ingrasciotta, Massimiliano Berretta, Gianluca Trifiro, Claudio Guarneri
Summary: Cancer is a common comorbidity linked to chronic cutaneous inflammatory diseases like psoriasis and hidradenitis suppurativa. The debate on whether current drugs increase cancer risk remains unsolved. New therapies, such as biologics, have enhanced treatment options but also pose a risk of non-melanoma skin cancers.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xinglei Shen, Daniel E. Spratt, Stacie B. Dusetzina, Ronald C. Chen
Summary: This study evaluated the variation in commercial insurance coverage and its impact on access to cancer care. The analysis of coverage determinations across the nation revealed wide disparities in policy. The findings highlight the need for more consistent methodology in assessing medical necessity to address the unequal access to cancer procedures based on residence and age.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Soumyajit Roy, Yilun Sun, Cristopher J. D. Wallis, Scott C. Morgan, Scott Grimes, Julia Malone, Amar U. Kishan, Dibya Mukherjee, Daniel E. Spratt, Fred Saad, Shawn Malone
Summary: This study developed and validated a multivariable prognostic model to predict overall survival (OS) in metastatic castrate sensitive prostate cancer (mCSPC). The model includes 11 prognostic variables and showed high predictive accuracy on a testing set.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Richard L. Cantley, Xiaoming Wang, Zachery R. Reichert, Arul M. Chinnaiyan, Rahul Mannan, Xuhong Cao, Daniel E. Spratt, Ulka N. Vaishampayan, Joshi J. Alumkal, Todd M. Morgan, Ganesh Palapattu, Matthew S. Davenport, Liron Pantanowitz, Rohit Mehra
Summary: Fine needle aspiration (FNA) can be used to diagnose metastatic prostatic cancer (MPC) based on typical cytomorphologic and immunohistochemical (IHC) features, but the diagnosis may be complicated by atypical phenotypes induced by androgen deprivation therapy (ADT). Careful assessment of cytologic and biomarker features can provide important therapeutic and prognostic information in MPC.
CANCER CYTOPATHOLOGY
(2023)
Article
Oncology
Sagar A. Patel, Ting Martin Ma, Jessica K. Wong, Bradley J. Stish, Robert T. Dess, Avinash Pilar, Chandana Reddy, Trude B. Wedde, Wolfgang A. Lilleby, Ryan Fiano, Gregory S. Merrick, Richard G. Stock, D. Jeffrey Demanes, Brian J. Moran, Phuoc T. Tran, Daniel J. Krauss, Eyad I. Abu-Isa, Thomas M. Pisansky, C. Richard Choo, Daniel Y. Song, Stephen Greco, Curtiland Deville, Theodore L. DeWeese, Derya Tilki, Jay P. Ciezki, R. Jeffrey Karnes, Nicholas G. Nickols, Matthew B. Rettig, Felix Y. Feng, Alejandro Berlin, Jonathan D. Tward, Brian J. Davis, Robert E. Reiter, Paul C. Boutros, Tahmineh Romero, Eric M. Horwitz, Rahul D. Tendulkar, Michael L. Steinberg, Daniel E. Spratt, Michael Xiang, Amar U. Kishan
Summary: For very-high-risk prostate cancer patients, the addition of brachytherapy to external beam radiation therapy with androgen deprivation therapy did not significantly improve outcomes compared to radiation therapy alone.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Pathology
Rahul Mannan, Xiaoming Wang, Pushpinder S. Bawa, Yuping Zhang, Stephanie L. Skala, Anya K. Chinnaiyan, Aniket Dagar, Lisha Wang, Sylvia B. Zelenka-Wang, Lisa M. McMurry, Nikita Daniel, Xuhong Cao, Ankur R. Sangoi, Sounak Gupta, Ulka N. Vaishampayan, Khaled S. Hafez, Todd M. Morgan, Daniel E. Spratt, Maria S. Tretiakova, Pedram Argani, Arul M. Chinnaiyan, Saravana M. Dhanasekaran, Rohit Mehra
Summary: LINC01187 is a novel biomarker that enhances the currently used KIT assay and facilitates microscopic analysis in routine surgical pathology practice.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Urology & Nephrology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.
Letter
Oncology
Cem Onal, Duygu Sezen, Ezgi Oymak, Yasemin Bolukbasi
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Review
Oncology
Simon K. B. Spohn, Cederic Draulans, Amar U. Kishan, Daniel Spratt, Ashley Ross, Tobias Maurer, Derya Tilki, Alejandro Berlin, Pierre Blanchard, Sean Collins, Peter Bronsert, Ronald Chen, Alan Dal Pra, Gert de Meerleer, Thomas Eade, Karin Haustermans, Tobias Holscher, Stefan Hocht, Pirus Ghadjar, Elai Davicioni, Matthias Heck, Linda G. W. Kerkmeijer, Simon Kirste, Nikolaos Tselis, Phuoc T. Tran, Michael Pinkawa, Pascal Pommier, Constantinos Deltas, Nina-Sophie Schmidt-Hegemann, Thomas Wiegel, Thomas Zilli, Alison C. Tree, Xuefeng Qiu, Vedang Murthy, Jonathan I. Epstein, Christian Graztke, Xin Gao, Anca L. Grosu, Sophia C. Kamran, Constantinos Zamboglou
Summary: Current risk-stratification systems for prostate cancer do not adequately reflect the disease heterogeneity. Genomic classifiers show promise in improving risk stratification after surgery, but limited data exist for patients treated with radiation therapy or in advanced stages of the disease. A systematic review and expert survey were conducted to evaluate the role of genomic classifiers in radiation therapy and identify future research areas for personalized treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Paul L. Nguyen, Huei-Chung (Rebecca) Huang, Daniel E. Spratt, Elai Davicioni, Howard M. Sandler, William U. Shipley, Jason A. Efstathiou, Jeffry P. Simko, Alan Pollack, Adam P. Dicker, Mack Roach III, Seth A. Rosenthal, Kenneth L. Zeitzer, Lucas C. Mendez, Alan C. Hartford, William A. Hall, Anand B. Desai, Rachel A. Rabinovitch, Christopher A. Peters, Joseph P. Rodgers, Phuoc Tran, Felix Y. Feng
Summary: The study validates the performance of Decipher genomic classifier (GC) in pretreatment biopsy samples. The GC score is independently associated with distant metastases, prostate cancer-specific mortality, and overall survival, providing valuable prognostic information for personalized decision-making.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Phuoc T. Tran, Kathryn Lowe, Hua-Ling Tsai, Daniel Y. Song, Arthur Y. Hung, Jason W. D. Hearn, Steven Miller, James A. Proudfoot, Matthew P. Deek, Ryan Phillips, Tamara Lotan, Channing J. Paller, Catherine H. Marshall, Mark Markowski, Shirl Dipasquale, Samuel Denmeade, Michael Carducci, Mario Eisenberger, Theodore L. DeWeese, Matthew Orton, Curtiland Deville, Elai Davicioni, Stanley L. Liauw, Elisabeth I. Heath, Stephen Greco, Neil B. Desai, Daniel E. Spratt, Felix Feng, Hao Wang, Tomasz M. Beer, Emmanuel S. Antonarakis
Summary: This study aimed to investigate the effect of enzalutamide on freedom from PSA progression in men with recurrent prostate cancer after radical prostatectomy. The results showed that enzalutamide monotherapy for 6 months in combination with salvage radiation therapy delayed PSA progression and was safe for high-risk patients with postoperative recurrence.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Randy A. Vince, Ralph Jiang, Merrick Bank, Jake Quarles, Milan Patel, Yilun Sun, Holly Hartman, Nicholas G. Zaorsky, Angela Jia, Jonathan Shoag, Robert T. Dess, Brandon A. Mahal, Kristian Stensland, Nicholas W. Eyrich, Mariana Seymore, Rebecca Takele, Todd M. Morgan, Matthew Schipper, Daniel E. Spratt
Summary: This meta-analysis demonstrates that the interaction between race and social determinants of health (SDOH) is associated with racial disparities in prostate cancer outcomes. Black patients have higher prostate cancer-specific mortality (PCSM) than White patients in studies with minimal accounting for SDOH, but lower PCSM in studies with greater accounting for SDOH. The findings underscore the importance of considering SDOH variables in research to promote health equity.
Article
Endocrinology & Metabolism
Soumyajit Roy, Christopher J. D. Wallis, Scott C. Morgan, Amar U. Kishan, Amy Tu Trinh Le, Julia Malone, Yilun Sun, Daniel E. Spratt, Fred Saad, Shawn Malone
Summary: This study analyzed the data from the ACIS study to determine if synchronous versus metachronous metastatic presentation is associated with survival and treatment response in docetaxel naive metastatic castrate resistant prostate cancer (mCRPC). The results showed that the stage of metastasis was not associated with disease progression, and there was no significant difference in the efficacy of treatment with docetaxel.
Article
Oncology
Ting Martin Ma, Felix Y. Feng, Seth A. Rosenthal, Matthew B. Rettig, Ann C. Raldow, Daniel E. Spratt, Michael Xiang, Amar U. Kishan
Summary: By comparing prostate cancer-specific mortality in patients from a real-world setting with those on a clinical trial, we found that trial patients had better outcomes, especially among Black patients, indicating significant racial disparities in the real world.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Correction
Health Care Sciences & Services
Andre J. Esteva, Jean Feng, Douwe van der Wal, Shih-Cheng Huang, Jeffry Simko, Sandy E. DeVries, Emmalyn Chen, Edward Schaeffer, Todd Morgan, Yilun Sun, Amirata A. Ghorbani, Nikhil Naik, Dhruv G. Nathawani, Richard D. Socher, Jeff L. Michalski, Mack R. Roach III, Thomas G. Pisansky, Jedidiah Monson, Farah A. Naz, James Wallace, Michelle M. Ferguson, Jean-Paul T. Bahary, James E. Zou, Matthew Lungren, Serena Y. Yeung, Ashley Ross, Howard M. Sandler, Phouc T. Tran, Daniel E. Spratt, Stephanie Pugh, Felix Y. Feng, Osama Mohamad
NPJ DIGITAL MEDICINE
(2023)
Article
Oncology
Clayton P. Smith, James A. Proudfoot, Paul C. Boutros, Robert E. Reiter, Luca Valle, Matthew B. Rettig, Nicholas G. Nickols, Felix Y. Feng, Paul L. Nguyen, Himanshu Nagar, Daniel E. Spratt, Gert Attard, Adam Weiner, Joanne B. Weidhaas, Jeremie Calais, T. Martin Ma, Elai Davicioni, Michael Xiang, Amar U. Kishan
Summary: PSMA PET has higher specificity and sensitivity than conventional imaging, and it can predict the risk of distant metastasis in high-risk and very high-risk prostate cancer patients. The risk of upstaging on PSMA PET is significantly correlated with the Decipher genetic score. Further studies are needed to explore the causal pathways between PSMA findings, Decipher scores, extraprostatic disease, and long-term clinical outcomes.
EUROPEAN UROLOGY ONCOLOGY
(2023)